Related Experiment Video
Updated: Jun 20, 2026

Universal Screening for Prevention of Reading, Writing, and Math Disabilities in Spanish
Published on: July 18, 2020
Prevalence of early neurodevelopmental disabilities in Mexico: a systematic review
Adrián Poblano1, Carmina Arteaga, Guillermina García-Sánchez
1Laboratory of Cognitive Neurophysiology, National Institute of Rehabilitation, Mexico City, Mexico. drdeaf@latinmail.com
Objective:
Early neurodevelopment disabilities (END) such as cerebral palsy (CP), deafness, blindness, epilepsy, and mental retardation (MR) are very important public health concerns. Although no strong data on END can be obtained in Mexico, the few papers concerning END epidemiology deserve systematic and critical review. Thus, this was the objective of the present paper.
Method:
We performed a systematic review of papers published reporting on the prevalence of END in Mexico. We performed a search in several medical data bases such as PubMed, Artemisa, ImBioMed, and LiLaCS. Each paper was downloaded, read and discussed. We only selected papers published between 1999 and 2008.
Results:
No data on CP and epilepsy prevalence in infants have been found. Data on deafness prevalence report hearing loss in 0.65/1,000 healthy newborns, and in 2.6/100 in high-risk very premature infants. With regard to blindness, prevalence of retinopathy of premature infants in any stage was reported at ca 10.61 and 22.2/100 in high-risk premature infants. Congenital hypothyroidism (CH) prevalence in infants was found in 4.2/10,000 live newborns after a national universal screening survey.
Conclusion:
No universal data regarding the prevalence of END in Mexico have been investigated, with the exception of CH. Mexico needs more research to determine epidemiologic data focused on designing actions to prevent, treat, and rehabilitate END.
Related Concept Videos
Learning Disabilities
Dyslexia
Dyslexia is a...
Intellectual Disability
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
